UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 396

Sortiert nach

Gender effects in cancer treatment and outcome

British journal of haematology, 2021-07, Vol.194 (2), p.229-230

Dutcher, Janice P.

2021

Link zum Volltext

Verfügbarkeit prüfen

Management of hepatitis B in the era of checkpoint inhibition

Journal for immunotherapy of cancer, 2020-02, Vol.8 (1), p.e000276

Dutcher, Janice

2020

Link zum Volltext

Verfügbarkeit prüfen

Update on the biology and management of renal cell carcinoma

Journal of Investigative Medicine, 2019-01, Vol.67 (1), p.1-10

Dutcher, Janice P

2019

Link zum Volltext

Verfügbarkeit prüfen

“Pseudoprogression”: more than semantics

Cancer Immunology, Immunotherapy, 2018-09, Vol.67 (9), p.1473-1474

Dutcher, Janice P.

2018

Link zum Volltext

Verfügbarkeit prüfen

Phase II Study of Axitinib in Sorafenib-Refractory Metastatic Renal Cell Carcinoma

Journal of clinical oncology, 2009-09, Vol.27 (27), p.4462-4468

2009

Link zum Volltext

Verfügbarkeit prüfen

Recent developments in the treatment of renal cell carcinoma

Therapeutic Advances in Urology, 2013-12, Vol.5 (6), p.338-353

Dutcher, Janice P.

2013

Link zum Volltext

Verfügbarkeit prüfen

EXPRESS: Families with Multiple Individuals with Acute Leukemia in Their Pedigrees

Journal of investigative medicine, 2024-06, p.10815589241262735

2024

Link zum Volltext

Verfügbarkeit prüfen

Families with non-Hodgkin lymphoma and plasma cell dyscrasias in their pedigrees

Journal of investigative medicine, 2024-01, Vol.72 (1), p.26-31

2024

Link zum Volltext

Verfügbarkeit prüfen

Predicting Renal Cancer Recurrence: Defining Limitations of Existing Prognostic Models With Prospective Trial-Based Validation

Journal of clinical oncology, 2019-08, Vol.37 (23), p.2062-2071

2019

Link zum Volltext

Verfügbarkeit prüfen

Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206

Journal of clinical oncology, 2010-05, Vol.28 (13), p.2137-2143

2010

Link zum Volltext

Verfügbarkeit prüfen

Axitinib in Metastatic Renal Cell Carcinoma: Results of a Pharmacokinetic and Pharmacodynamic Analysis

Journal of clinical pharmacology, 2013-05, Vol.53 (5), p.491-504

2013

Link zum Volltext

Verfügbarkeit prüfen

Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206

Journal of clinical oncology, 2008-11, Vol.26 (33), p.5422-5428

2008

Link zum Volltext

Verfügbarkeit prüfen

Drug-Related Pneumonitis in Patients With Advanced Renal Cell Carcinoma Treated With Temsirolimus

Journal of clinical oncology, 2011-05, Vol.29 (13), p.1750-1756

2011

Link zum Volltext

Verfügbarkeit prüfen

Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition

Journal for immunotherapy of cancer, 2019-02, Vol.7 (1), p.49-7, Article 49

2019

Link zum Volltext

Verfügbarkeit prüfen

Randomized Phase II Study of Multiple Dose Levels of CCI-779, a Novel Mammalian Target of Rapamycin Kinase Inhibitor, in Patients With Advanced Refractory Renal Cell Carcinoma

Journal of clinical oncology, 2004-03, Vol.22 (5), p.909-918

2004

Link zum Volltext

Verfügbarkeit prüfen

Predicting Disease Recurrence, Early Progression, and Overall Survival Following Surgical Resection for High-risk Localized and Locally Advanced Renal Cell Carcinoma

European urology, 2021-07, Vol.80 (1), p.20-31

2021

Link zum Volltext

Verfügbarkeit prüfen

Interleukin‐2 Can Cure Kidney Cancer

The oncologist (Dayton, Ohio), 2018-09, Vol.23 (9), p.e107-e107

2018

Link zum Volltext

Verfügbarkeit prüfen

BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804)

Journal of clinical oncology, 2015-07, Vol.33 (21), p.2384-2391

2015

Link zum Volltext

Verfügbarkeit prüfen

Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial

JAMA oncology, 2017-09, Vol.3 (9), p.1249

2017

Link zum Volltext

Verfügbarkeit prüfen

Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma

Journal of clinical oncology, 2005-01, Vol.23 (1), p.133-141

2005

Link zum Volltext

Verfügbarkeit prüfen

Local Recurrence Following Resection of Intermediate-High Risk Nonmetastatic Renal Cell Carcinoma: An Anatomical Classification and Analysis of the ASSURE (ECOG-ACRIN E2805) Adjuvant Trial

The Journal of urology, 2020-04, Vol.203 (4), p.684-689

2020

Link zum Volltext

Verfügbarkeit prüfen

Evolving Strategies for the Management of Hand–Foot Skin Reaction Associated with the Multitargeted Kinase Inhibitors Sorafenib and Sunitinib

The oncologist (Dayton, Ohio), 2008-09, Vol.13 (9), p.1001-1011

2008

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 396

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(322)
Mit Volltextzugriff
(345)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(395)
Japanisch
(24)
Russisch
(1)

Erscheinungsjahr

n.n

Thema

Humans
(243)
Science & Technology
(229)
Life Sciences & Biomedicine
(227)
Oncology
(166)
Male
(142)
Female
(134)
Middle Aged
(131)
Adult
(117)
Biological And Medical Sciences
(117)
Medical Sciences
(116)
Aged
(105)
Kidney Neoplasms - Drug Therapy
(59)
Pharmacology. Drug Treatments
(58)
Carcinoma, Renal Cell - Drug Therapy
(57)
Hematology
(57)
Antineoplastic Agents
(54)
Immunotherapy
(45)
Kidney Neoplasms - Pathology
(41)
Interleukin-2 - Therapeutic Use
(38)
Antineoplastic Agents - Therapeutic Use
(36)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Gender effects in cancer treatment and outcome

Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial

Management of hepatitis B in the era of checkpoint inhibition

Update on the biology and management of renal cell carcinoma

“Pseudoprogression”: more than semantics

Phase II Study of Axitinib in Sorafenib-Refractory Metastatic Renal Cell Carcinoma

Recent developments in the treatment of renal cell carcinoma

EXPRESS: Families with Multiple Individuals with Acute Leukemia in Their Pedigrees

Families with non-Hodgkin lymphoma and plasma cell dyscrasias in their pedigrees

Predicting Renal Cancer Recurrence: Defining Limitations of Existing Prognostic Models With Prospective Trial-Based Validation

Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206

Axitinib in Metastatic Renal Cell Carcinoma: Results of a Pharmacokinetic and Pharmacodynamic Analysis

Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206

Drug-Related Pneumonitis in Patients With Advanced Renal Cell Carcinoma Treated With Temsirolimus

Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition

Randomized Phase II Study of Multiple Dose Levels of CCI-779, a Novel Mammalian Target of Rapamycin Kinase Inhibitor, in Patients With Advanced Refractory Renal Cell Carcinoma

Predicting Disease Recurrence, Early Progression, and Overall Survival Following Surgical Resection for High-risk Localized and Locally Advanced Renal Cell Carcinoma

Interleukin‐2 Can Cure Kidney Cancer

BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804)

Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America

Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial

Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma

The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma

Local Recurrence Following Resection of Intermediate-High Risk Nonmetastatic Renal Cell Carcinoma: An Anatomical Classification and Analysis of the ASSURE (ECOG-ACRIN E2805) Adjuvant Trial

Evolving Strategies for the Management of Hand–Foot Skin Reaction Associated with the Multitargeted Kinase Inhibitors Sorafenib and Sunitinib

Suchergebnisse filtern